Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith
  
rock climber on an overhang
The Trump Administration's move to dismiss or transfer a mifepristone case is not the worst outcome for industry, but still leaves some overhanging risk. (Shutterstock)

More from Litigation

More from Legal & IP